Umecrine

Umecrine Cognition is a clinical-stage Swedish biotechnology company focused on developing novel treatments for CNS-related disorders caused by endogenous neurosteroids. The company's lead candidate, golexanolone, is a first-in-class GABAA receptor modulating steroid antagonist designed to address cognitive and motor impairment in patients with liver disease and other neurological conditions. By targeting the GABAergic system, Umecrine Cognition aims to restore normal brain function in conditions such as hepatic encephalopathy and primary biliary cholangitis. The company is a portfolio company of Karolinska Development and operates out of Stockholm, Sweden.